360 related articles for article (PubMed ID: 10808055)
21. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
Kim WK; Kan Y; Ganea D; Hart RP; Gozes I; Jonakait GM
J Neurosci; 2000 May; 20(10):3622-30. PubMed ID: 10804204
[TBL] [Abstract][Full Text] [Related]
22. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
Jiang X; Wang HY; Yu J; Ganea D
Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
[TBL] [Abstract][Full Text] [Related]
23. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
[TBL] [Abstract][Full Text] [Related]
24. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
[TBL] [Abstract][Full Text] [Related]
26. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs.
Dickinson T; Fleetwood-Walker SM; Mitchell R; Lutz EM
Neuropeptides; 1997 Apr; 31(2):175-85. PubMed ID: 9179871
[TBL] [Abstract][Full Text] [Related]
27. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies.
Delgado M; Pozo D; Martinez C; Leceta J; Calvo JR; Ganea D; Gomariz RP
J Immunol; 1999 Feb; 162(4):2358-67. PubMed ID: 9973516
[TBL] [Abstract][Full Text] [Related]
28. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.
Ekblad E; Jongsma H; Brabet P; Bockaert J; Sundler F
Ann N Y Acad Sci; 2000; 921():137-47. PubMed ID: 11193817
[TBL] [Abstract][Full Text] [Related]
29. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.
Delgado M
Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537
[TBL] [Abstract][Full Text] [Related]
30. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
31. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731
[TBL] [Abstract][Full Text] [Related]
32. The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor.
Sano H; Miyata A; Horio T; Nishikimi T; Matsuo H; Kangawa K
Regul Pept; 2002 Nov; 109(1-3):107-13. PubMed ID: 12409222
[TBL] [Abstract][Full Text] [Related]
33. PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion.
Inagaki N; Kuromi H; Seino S
Ann N Y Acad Sci; 1996 Dec; 805():44-51; discussion 52-3. PubMed ID: 8993392
[TBL] [Abstract][Full Text] [Related]
34. Pituitary adenylate cyclase-activating peptide stimulates acute progesterone production in rat granulosa/Lutein cells via two receptor subtypes.
Gräs S; Hedetoft C; Pedersen SH; Fahrenkrug J
Biol Reprod; 2000 Jul; 63(1):206-12. PubMed ID: 10859261
[TBL] [Abstract][Full Text] [Related]
35. Functional and molecular diversity of PACAP/VIP receptors in cortical neurons and type I astrocytes.
Grimaldi M; Cavallaro S
Eur J Neurosci; 1999 Aug; 11(8):2767-72. PubMed ID: 10457173
[TBL] [Abstract][Full Text] [Related]
36. Pituitary adenylate cyclase-activating peptide and vasoactive intestinal peptide receptor expression in immortalized LHRH neurons.
Olcese J; McArdle CA; Middendorff R; Greenland K
J Neuroendocrinol; 1997 Dec; 9(12):937-43. PubMed ID: 9468019
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide receptors in rat intrinsic cardiac neurons.
DeHaven WI; Cuevas J
Neurosci Lett; 2002 Aug; 328(1):45-9. PubMed ID: 12123856
[TBL] [Abstract][Full Text] [Related]
38. [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system].
Hashimoto H
Yakugaku Zasshi; 2002 Dec; 122(12):1109-21. PubMed ID: 12510388
[TBL] [Abstract][Full Text] [Related]
39. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
Delgado M; Reduta A; Sharma V; Ganea D
J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
[TBL] [Abstract][Full Text] [Related]
40. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]